Indonesia’s diagnostics market is growing fast, and foreign brands that move now stand to capture serious ground. But breaking into this market is not simply a matter of having a world-class product.
For any American or European manufacturer shipping diagnostic kits, reagents, or analyzers into the Indonesian market, IVD registration Indonesia is a non-negotiable regulatory milestone that demands careful preparation, the right documentation, and a trusted local partner.
The government’s push to strengthen diagnostic infrastructure, particularly after the pandemic years, has created real commercial opportunities for high-quality in-vitro diagnostic products from established international markets.
Yet many foreign manufacturers arrive underprepared, underestimating how different the Indonesian regulatory landscape is from the EU or the U.S.
This guide breaks down everything a foreign brand needs to know: risk classification, laboratory testing requirements, technical documentation (CSDT), and the relevant Indonesian regulations.
Why Indonesia Is a Priority Market for IVD Brands?
Southeast Asia’s largest economy continues to invest heavily in its healthcare system. Under the Indonesian government’s JKN (Jaminan Kesehatan Nasional) universal health coverage program, demand for affordable and reliable diagnostic tools has surged at both the hospital and primary clinic level.
This is driving significant procurement of everything from simple glucose meters to complex molecular diagnostic platforms.
For American and European IVD companies, this demand signal is compelling. But accessing the market requires navigating the authority of two key ministries: the Ministry of Health (Kementerian Kesehatan, or KEMENKES), which oversees the medical device registration system, and the National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan, commonly known as 业务流程对象模型), which plays a supporting oversight role, particularly in areas involving reagent chemistry and biological substances.
| Key Regulatory Note: In Indonesia, all medical devices including IVDs must obtain a Nomor Izin Edar (NIE), which is the official product registration number issued by KEMENKES. Without the NIE, importing or distributing an IVD product is not permitted under Indonesian law. |
IVD Risk Classification in Indonesia: Classes A to D
Indonesia aligns its medical device and IVD classification system broadly with the ASEAN Medical Device Directive (AMDD) and ASEAN harmonized guidelines. Under Peraturan Menteri Kesehatan Nomor 62 Tahun 2017 tentang Izin Edar Alat Kesehatan, In-vitro Diagnostic, dan Perbekalan Kesehatan Rumah Tangga, IVDs are classified into four risk classes, each carrying different regulatory requirements.
Class A: Low Risk
Class A IVDs pose minimal risk to the individual or public. Products such as simple blood glucose monitoring strips and general urine testing kits fall into this category. Registration for Class A products is simplified: manufacturers may be eligible for a self-declaration pathway (Pernyataan Mandiri), which significantly reduces documentation burden and timeline.
Class B: Low-to-Medium Risk
Products such as hematology analyzers and standard biochemistry test kits are typically Class B. A simplified dossier is required, and KEMENKES conducts a formal review. Laboratory testing may or may not be required depending on the specific product and its intended use.
Class C: Medium-to-High Risk
Blood bank screening reagents, molecular diagnostics panels, and tests detecting chronic disease markers often fall under Class C. This class requires a full CSDT (Common Submission Dossier Template) submission backed by performance evidence, including analytical validation data. Laboratory testing at an accredited facility is mandatory.
Class D: High Risk
Class D covers IVDs used for screening life-threatening infectious diseases, including HIV, Hepatitis B and C, and blood grouping systems. These products carry the highest evidentiary burden: a complete CSDT dossier, robust clinical performance data, and mandatory testing against Indonesian National Standards (SNI) or equivalent ISO standards. This pathway typically takes 12-18 months from submission to approval.
IVD Risk Class Comparison at a Glance
The table below summarizes the four IVD risk classes, their representative product categories, regulatory pathways, indicative timelines, and laboratory testing obligations.
This is particularly relevant for brands assessing whether their product will require full in-vitro diagnostics BPOM documentation or a lighter-touch approach.
| Class | Examples | Registration Path | 时间线 | 实验室测试 |
| A (Low Risk) | Personal glucose meters, pregnancy test kits | Self-declaration (Pernyataan Mandiri) | 3-6个月 | Not required |
| B (Low-Medium) | Hematology analyzers, general chemistry tests | Simplified dossier + BPOM review | 6-9 months | Sometimes required |
| C (Medium-High) | Blood bank screening reagents, molecular diagnostics | Full CSDT dossier + lab evidence | 9-15 months | Required |
| D (High Risk) | HIV, Hepatitis screening kits, blood grouping | Full CSDT + clinical/performance data | 12-18 months | Mandatory (SNI/ISO) |
Note: Timelines are indicative and subject to KEMENKES workload, completeness of submission, and any additional data requests. Engaging a professional local partner often reduces these timelines significantly.
Laboratory Testing Requirements for IVD Products
One of the most commonly underestimated steps in the IVD registration process in Indonesia is laboratory testing.
Unlike some other markets where third-country clinical data is sufficient, Indonesian regulators often require performance testing conducted at a locally recognized or ISO 17025-accredited facility.
For Class C and Class D products, the testing scope typically covers:
• Analytical sensitivity and specificity under local conditions
• Cross-reactivity testing with locally relevant interfering substances
• Precision and reproducibility (within-run and between-run)
• Stability testing under Indonesian climate conditions (temperature, humidity)
• Comparative clinical performance against an established gold-standard method
Manufacturers should plan for laboratory testing early in the process. Sourcing an accredited laboratory that can handle their specific IVD category is not always straightforward, and some categories require coordination with academic hospitals or national reference laboratories.
| Practical Tip for Foreign Brands: Begin your laboratory accreditation and testing planning at least six months before your intended submission date. Test failures or protocol mismatches are among the top reasons for registration delays. A local regulatory consultant familiar with Indonesian lab requirements is invaluable here. |
Understanding the Technical Documentation: CSDT
The Common Submission Dossier Template (CSDT) is the ASEAN-harmonized technical file format required for Class C and Class D IVD submissions in Indonesia.
American and European manufacturers who are accustomed to EU IVDR technical documentation or FDA 510(k) submissions will find the CSDT structure somewhat familiar but with important regional differences.
A complete CSDT for IVD registration Indonesia includes the following core sections:
• Section 1: Device Description and Specification (including intended use, principle of operation, and labeling)
• Section 2: Design Verification and Validation (including design history, testing protocols, and verification evidence)
• Section 3: Manufacturing Information (facility details, quality system certification, ISO 13485 scope)
• Section 4: Clinical/Performance Evidence (analytical and, for Class D, clinical performance data)
• Section 5: Risk Management (ISO 14971 risk management file summary)
• Section 6: Post-Market Surveillance Plan (vigilance system and adverse event reporting protocol)
One critical difference for foreign brands: all documents submitted to KEMENKES must either be in Bahasa Indonesia or accompanied by a certified translation.
This requirement covers labeling, instructions for use (IFU), and key technical sections. Failing to provide compliant translations is a frequent cause of application rejection.
Key Indonesian Regulations for IVD Registration
Understanding the regulatory framework is essential before initiating any IVD registration application. The following regulations govern the registration, importation, and distribution of IVD products in Indonesia:
• Peraturan Menteri Kesehatan No. 62 Tahun 2017: The primary regulation governing the issuance of Izin Edar (marketing authorization) for medical devices, IVDs, and household health supplies. This regulation defines the classification system, application procedures, and post-market obligations.
• Peraturan Menteri Kesehatan No. 26 Tahun 2018: Governs the licensing of medical device distributors (IPAK), importers, and manufacturers, establishing the legal framework for who may submit an application.
• Peraturan Menteri Kesehatan No. 14 Tahun 2021: Addresses electronic submission procedures (E-Registration), streamlining parts of the application process for registered products.
• Peraturan BPOM No. 24 Tahun 2017: Relevant to in-vitro diagnostics BPOM oversight, particularly for biological-based reagents and diagnostic kits falling under pharmaceutical-adjacent classifications.
• SNI (Standar Nasional Indonesia): Indonesian National Standards applicable to specific IVD categories, particularly for Class D products. Compliance may be required as part of laboratory testing and product certification.
Closing: Navigating Your Path to Success with us
The path to successful IVD registration Indonesia is rarely linear. With evolving KEMENKES requirements and shifting timelines, navigating this complex landscape independently carries significant risk for international brands. In a fast-moving diagnostic market, every quarter spent stalled in the planning phase is an opportunity for your competitors to secure vital distributor networks and hospital listings.
Ultimately, what separates the brands that succeed quickly from those that struggle is not product quality, it is preparation and partnership. Working with a specialist firm bridges this gap, managing everything from initial product classification and CSDT preparation through to NIE issuance, so you can stay focused on commercial growth.
As your dedicated regulatory partner, ProductRegistrationIndonesia is ready to streamline your entry into the Indonesian market. We combine deep local expertise, established relationships, and hands-on experience across IVD categories to help international brands navigate the registration system efficiently and accurately. From laboratory coordination to submission management, our team ensures your compliance strategy is flawless.
The Indonesian market window is wide open. Partner with us today to ensure your documentation is ready, your risks are minimized, and your market entry is seamless.
常见问题
1. Does Indonesia accept CE marking or FDA clearance in place of local registration?
No. Indonesia does not grant automatic market access based on CE marking or FDA clearance. While these certifications are recognized as supporting evidence during the evaluation process, every IVD product must go through its own IVD registration Indonesia pathway under Kemenkes and, where applicable, BPOM oversight. International clearances can, however, significantly strengthen a company’s technical dossier and shorten review timelines.
2. What is the CSDT and how does it differ from a standard technical file?
The Common Submission Dossier Template (CSDT) is the ASEAN-harmonized format for medical device technical documentation. Unlike a standard CE technical file, which follows EU MDR/IVDR structure, the CSDT is specifically designed for ASEAN regulatory submissions and includes sections on product description, design verification, clinical/performance evidence, risk management, and post-market surveillance. For Class C and D IVDs targeting Indonesia, the CSDT is the required format.
3. Is a local Indonesian representative mandatory for foreign IVD brands?
Yes. Under Peraturan Menteri Kesehatan No. 62 Tahun 2017 and subsequent regulations, all foreign medical device manufacturers must appoint a licensed local representative in Indonesia. This entity, known as the Perwakilan Lokal or importer of record, is responsible for submitting the application to KEMENKES, maintaining post-market surveillance, and handling any product recalls or notifications. The local representative must hold a valid distribution license (Izin Distribusi) relevant to medical devices.
4. What laboratory testing is required for Class C and D in-vitro diagnostics BPOM submissions?
For Class C and Class D IVDs, Indonesian authorities typically require performance verification testing conducted at a laboratory recognized by the National Standardization Agency of Indonesia (BSN) or an ISO 17025-accredited facility. Tests evaluate analytical sensitivity, specificity, cross-reactivity, precision, and stability. For molecular diagnostics and infectious disease panels, clinical performance studies comparing the IVD against a gold-standard method are also expected. Manufacturers should ensure their test protocols align with the CSDT requirements and relevant Indonesian National Standards (SNI).
5. Can a foreign manufacturer apply for a medical device import permit directly?
No. Foreign manufacturers cannot apply directly for a medical device import permit in Indonesia. The application must be submitted by a locally registered company, which acts as the authorized importer and local representative. This company will hold the Nomor Izin Edar (NIE), which is Indonesia’s product registration number. Maintaining a strong, compliant relationship with your local partner is therefore critical to your long-term market access strategy.
